Nothing Special   »   [go: up one dir, main page]

WO2003050245A3 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Therapeutic polypeptides, nucleic acids encoding same, and methods of use Download PDF

Info

Publication number
WO2003050245A3
WO2003050245A3 PCT/US2002/038594 US0238594W WO03050245A3 WO 2003050245 A3 WO2003050245 A3 WO 2003050245A3 US 0238594 W US0238594 W US 0238594W WO 03050245 A3 WO03050245 A3 WO 03050245A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nucleic acids
polypeptides
polypeptide
acids encoding
Prior art date
Application number
PCT/US2002/038594
Other languages
French (fr)
Other versions
WO2003050245A8 (en
WO2003050245A2 (en
Inventor
John P Ii Alsobrook
David W Anderson
Ferenc L Boldog
Original Assignee
Curagen Corp
John P Ii Alsobrook
David W Anderson
Ferenc L Boldog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/309,290 external-priority patent/US20040023241A1/en
Application filed by Curagen Corp, John P Ii Alsobrook, David W Anderson, Ferenc L Boldog filed Critical Curagen Corp
Priority to CA002467721A priority Critical patent/CA2467721A1/en
Priority to JP2003551267A priority patent/JP2006507793A/en
Priority to AU2002359579A priority patent/AU2002359579A1/en
Priority to EP02794126A priority patent/EP1504026A4/en
Publication of WO2003050245A2 publication Critical patent/WO2003050245A2/en
Publication of WO2003050245A8 publication Critical patent/WO2003050245A8/en
Publication of WO2003050245A3 publication Critical patent/WO2003050245A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)

Abstract

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
PCT/US2002/038594 2001-12-05 2002-12-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use WO2003050245A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002467721A CA2467721A1 (en) 2001-12-05 2002-12-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2003551267A JP2006507793A (en) 2001-12-05 2002-12-03 Therapeutic polypeptides, nucleic acids encoding the same, and methods of use
AU2002359579A AU2002359579A1 (en) 2001-12-05 2002-12-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP02794126A EP1504026A4 (en) 2001-12-05 2002-12-03 Therapeutic polypeptides, nucleic acids encodings same, and methods of use

Applications Claiming Priority (38)

Application Number Priority Date Filing Date Title
US33660001P 2001-12-05 2001-12-05
US60/336,600 2001-12-05
US33828501P 2001-12-07 2001-12-07
US60/338,285 2001-12-07
US34134601P 2001-12-12 2001-12-12
US60/341,346 2001-12-12
US34147701P 2001-12-17 2001-12-17
US34154001P 2001-12-17 2001-12-17
US60/341,540 2001-12-17
US60/341,477 2001-12-17
US34259201P 2001-12-20 2001-12-20
US60/342,592 2001-12-20
US34429701P 2001-12-27 2001-12-27
US60/344,297 2001-12-27
US34490301P 2001-12-31 2001-12-31
US60/344,903 2001-12-31
US37328802P 2002-04-17 2002-04-17
US60/373,288 2002-04-17
US38098102P 2002-05-15 2002-05-15
US60/380,981 2002-05-15
US38149502P 2002-05-17 2002-05-17
US60/381,495 2002-05-17
US38374402P 2002-05-28 2002-05-28
US38353402P 2002-05-28 2002-05-28
US60/383,744 2002-05-28
US60/383,534 2002-05-28
US38382902P 2002-05-29 2002-05-29
US38402402P 2002-05-29 2002-05-29
US60/384,024 2002-05-29
US60/383,829 2002-05-29
US40178802P 2002-08-07 2002-08-07
US60/401,788 2002-08-07
US40635302P 2002-08-26 2002-08-26
US60/406,353 2002-08-26
US42275602P 2002-10-31 2002-10-31
US60/422,756 2002-10-31
US10/309,290 US20040023241A1 (en) 2001-12-05 2002-12-02 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US10/309,290 2002-12-02

Publications (3)

Publication Number Publication Date
WO2003050245A2 WO2003050245A2 (en) 2003-06-19
WO2003050245A8 WO2003050245A8 (en) 2004-05-13
WO2003050245A3 true WO2003050245A3 (en) 2004-12-16

Family

ID=32303940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038594 WO2003050245A2 (en) 2001-12-05 2002-12-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Country Status (5)

Country Link
EP (1) EP1504026A4 (en)
JP (1) JP2006507793A (en)
AU (1) AU2002359579A1 (en)
CA (1) CA2467721A1 (en)
WO (1) WO2003050245A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534017A (en) 2005-03-30 2008-08-28 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Modulators of DKKL-1 splice products for cancer diagnosis and therapy
JPWO2008093827A1 (en) * 2007-02-01 2010-05-20 財団法人大阪産業振興機構 Central nervous system disorder therapeutic agent and method for treating central nervous system disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512668A (en) * 1997-08-06 2001-08-28 ザイモジェネティクス，インコーポレイティド Lipocalin homolog
US20030157506A1 (en) * 2000-02-11 2003-08-21 Jean-Francois Meritet Interferon-alpha induced genes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] LASSAGNE H. ET AL: "Cloning of a human lacrimal lipocalin secreted in tears", XP002982120, accession no. STN Database accession no. (X67647) *
EXP. EYE RES., vol. 56, no. 5, 1993, pages 605 - 609 *
See also references of EP1504026A4 *

Also Published As

Publication number Publication date
WO2003050245A8 (en) 2004-05-13
EP1504026A4 (en) 2005-12-21
JP2006507793A (en) 2006-03-09
WO2003050245A2 (en) 2003-06-19
CA2467721A1 (en) 2003-06-19
EP1504026A2 (en) 2005-02-09
AU2002359579A1 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003057158A3 (en) Method of treating apoptosis and compositions thereof
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002068649A3 (en) Proteins and nucleic acids encoding same
WO2002081518A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002098917A3 (en) Human proteins and nucleic acids encoding same
WO2002029058A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2001090155A3 (en) Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2001029217A3 (en) Novel polypeptides and polynucleotides encoding same
WO2002055704A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002081510A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002055702A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2003031571A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002066643A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
WO2003040329A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003085124A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002057452A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002068647A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2001025436A3 (en) Endozepine-like polypeptides and polynucleotides encoding same
WO2003064589A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 25/2003 UNDER (30) REPLACE "NOT FURNISHED, 31 OCTOBER 2002 (31.10.2002), US" BY "60/422,756, 31 OCTOBER 2002 (31.10.2002), US" AND REPLACE "NOT FURNISHED , 2 DECEMBER 2002 (02.12.2002), US" BY "10/309,290, 2 DECEMBER 2002 (02.12.2002), US"

WWE Wipo information: entry into national phase

Ref document number: 2002359579

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2467721

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003551267

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002794126

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002794126

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002794126

Country of ref document: EP